BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20570146)

  • 1. 2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.
    Carter DS; Cai HY; Lee EK; Iyer PS; Lucas MC; Roetz R; Schoenfeld RC; Weikert RJ
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3941-5. PubMed ID: 20570146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
    Gray DL; Xu W; Campbell BM; Dounay AB; Barta N; Boroski S; Denny L; Evans L; Stratman N; Probert A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6604-7. PubMed ID: 19854053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Synthesis and antidepressant activities of aryl alkanol piperidine derivatives].
    Zheng YY; Gao K; Weng ZJ; Li JQ
    Yao Xue Xue Bao; 2010 Mar; 45(3):324-9. PubMed ID: 21351508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.
    Shaw AM; Boules M; Zhang Y; Williams K; Robinson J; Carlier PR; Richelson E
    Eur J Pharmacol; 2007 Jan; 555(1):30-6. PubMed ID: 17109850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
    Shao L; Wang F; Malcolm SC; Ma J; Hewitt MC; Campbell UC; Bush LR; Spicer NA; Engel SR; Saraswat LD; Hardy LW; Koch P; Schreiber R; Spear KL; Varney MA
    Bioorg Med Chem; 2011 Jan; 19(1):663-76. PubMed ID: 21093273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.
    Micheli F; Cavanni P; Andreotti D; Arban R; Benedetti R; Bertani B; Bettati M; Bettelini L; Bonanomi G; Braggio S; Carletti R; Checchia A; Corsi M; Fazzolari E; Fontana S; Marchioro C; Merlo-Pich E; Negri M; Oliosi B; Ratti E; Read KD; Roscic M; Sartori I; Spada S; Tedesco G; Tarsi L; Terreni S; Visentini F; Zocchi A; Zonzini L; Di Fabio R
    J Med Chem; 2010 Jul; 53(13):4989-5001. PubMed ID: 20527970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
    Lee KH; Park CE; Min KH; Shin YJ; Chung CM; Kim HH; Yoon HJ; Won-Kim ; Ryu EJ; Shin YJ; Nam HS; Cho JW; Lee HY
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5567-71. PubMed ID: 20724153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.
    Sabatucci JP; Mahaney PE; Leiter J; Johnston G; Burroughs K; Cosmi S; Zhang Y; Ho D; Deecher DC; Trybulski E
    Bioorg Med Chem Lett; 2010 May; 20(9):2809-12. PubMed ID: 20378347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors.
    Han Y; Han M; Shin D; Song C; Hahn HG
    J Med Chem; 2012 Sep; 55(18):8188-92. PubMed ID: 22938049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor.
    Hou J; Xing Y; Zuo D; Wu Y; Tian J; Meng Q; Yang M
    Physiol Behav; 2015 Jan; 138():141-9. PubMed ID: 25447484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
    Carlier PR; Lo MM; Lo PC; Richelson E; Tatsumi M; Reynolds IJ; Sharma TA
    Bioorg Med Chem Lett; 1998 Mar; 8(5):487-92. PubMed ID: 9871604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
    McComas CC; Vu AT; Mahaney PE; Cohn ST; Fensome A; Marella MA; Nogle L; Trybulski EJ; Ye F; Zhang P; Alfinito P; Bray J; Johnston G; Koury E; Deecher DC
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4929-31. PubMed ID: 18771916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
    Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
    J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors.
    Paudel S; Acharya S; Yoon G; Kim KM; Cheon SH
    Bioorg Med Chem; 2017 Apr; 25(7):2266-2276. PubMed ID: 28274674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple reuptake inhibitors: Design, synthesis and structure-activity relationship of benzylpiperidine-tetrazoles.
    Paudel S; Min X; Acharya S; Khadka DB; Yoon G; Kim KM; Cheon SH
    Bioorg Med Chem; 2017 Oct; 25(20):5278-5289. PubMed ID: 28807575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative structure-activity relationship analysis of aryl alkanol piperazine derivatives with antidepressant activities.
    Chen KX; Li ZG; Xie HY; Gao JR; Zou JW
    Eur J Med Chem; 2009 Nov; 44(11):4367-75. PubMed ID: 19581024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.
    Shao L; Hewitt MC; Wang F; Malcolm SC; Ma J; Campbell JE; Campbell UC; Engel SR; Spicer NA; Hardy LW; Schreiber R; Spear KL; Varney MA
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1438-41. PubMed ID: 21310609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
    Bannwart LM; Carter DS; Cai HY; Choy JC; Greenhouse R; Jaime-Figueroa S; Iyer PS; Lin CJ; Lee EK; Lucas MC; Lynch SM; Madera AM; Moore A; Ozboya K; Raptova L; Roetz R; Schoenfeld RC; Stein KA; Steiner S; Villa M; Weikert RJ; Zhai Y
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6062-6. PubMed ID: 18954985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological activities of 1-aryl-1,4-diazepan-2-one derivatives as novel triple reuptake inhibitors.
    Honda E; Ishichi Y; Kimura E; Yoshikawa M; Kanzaki N; Nakagawa H; Terao Y; Suzuki A; Kawai T; Arakawa Y; Ohta H; Terauchi J
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3898-902. PubMed ID: 25017029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.
    Zhang P; Terefenko EA; McComas CC; Mahaney PE; Vu A; Trybulski E; Koury E; Johnston G; Bray J; Deecher D
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6067-70. PubMed ID: 18951020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.